PDT – the final word
The Selectivity Myth
The 3-4× selectivity ratio often cited for ALA-PDT is optimistic marketing. For skin cancers specifically, the research reveals a more sobering reality: selectivity is inconsistent, often absent, and frequently based on penetration artifacts rather than metabolic targeting.
What the Studies Actually Show
Basal Cell Carcinoma – No Selectivity The most damning study examined 16 BCCs and found “no selectivity for tumor tissue versus normal epidermis” after topical ALA application. Many nodular and infiltrating BCCs showed “little or no PpIX in deep tumor lobules”. Any apparent selectivity was attributed to enhanced penetration through damaged stratum corneum, not metabolic differences.
UV-Induced Skin Tumors (Actinic Keratoses/SCC) Studies in mice with 1-2mm UV-induced lesions (equivalent to AKs or SCCs in situ) showed higher PpIX in tumors versus normal skin, but selectivity was concentration-dependent. Higher ratios required 8-16% ALA concentrations versus 2%. Even with apparent selectivity, PpIX photobleaching rates were “significantly higher in normal mouse skin than in tumours”, suggesting normal tissue was still being damaged.
Condylomata (HPV Lesions) Only 17 of 25 condylomata showed significantly greater fluorescence than adjacent normal skin, with peak ratios at 2 hours. The mechanism was “enhanced stratum corneum permeability” rather than metabolic selectivity.
Comparative Analysis When PDT selectivity was compared across photosensitizers, the ranking was Chlorin e6 > ALA-PpIX > Photofrin II, placing ALA-PDT in the middle range for selectivity—hardly the precision targeting often claimed.
Why Selectivity Fails in Skin Cancer
The Penetration Artifact Most apparent “selectivity” comes from barrier disruption, not metabolic differences. Dysplastic skin has compromised stratum corneum that allows better ALA penetration. This creates the illusion of targeting when you’re really just seeing enhanced drug delivery through damaged barriers.
Metabolic Reality Research shows “tumor-specific PPIX accumulation is generated by ALA conversion rather than by initial ALA uptake” with “no significant overall difference in uptake of ALA”. The problem: while cancer cells may have altered ferrochelatase activity, this advantage is minimal and easily overwhelmed by surface effects.
Depth Limitations Studies consistently show poor PpIX accumulation in deep tumor lobules, meaning PDT primarily affects surface layers regardless of selectivity. For infiltrative cancers, this is therapeutically insufficient.
Clinical Implications
The Selectivity Collapse Even marginal selectivity depends on optimal conditions. When clinics cut corners with:
- 30-minute incubation (instead of 2-3 hours)
- Poor surface cleaning
- Multi-wavelength light systems
Whatever minimal selectivity exists disappears entirely, turning targeted therapy into indiscriminate surface damage.
Depth Limitation with Short Incubation The 30-minute protocol creates a double failure: at this timeframe, most ALA remains in the stratum corneum rather than penetrating into the epidermis where dysplastic cells actually reside. The result is non-selective and superficial damage—maximum pain for minimal therapeutic depth. You get surface burning without reaching the cells that matter.
Why 5-FU Pre-treatment Matters The week of 5-FU actually creates the metabolic vulnerabilities that ALA-PDT is supposed to target naturally. 5-FU “induces selective cytotoxic stress in actinically damaged cells” and “increases intracellular PpIX accumulation”, enhancing whatever marginal selectivity exists.
Tissue Tolerance vs. Precision PDT “works” in skin not because it’s selective, but because skin tolerates collateral damage well. The surrounding tissue can afford to take a hit while abnormal cells hopefully take a bigger one. It’s functional but crude.
Bottom Line
PDT selectivity for skin cancers is largely a penetration artifact masquerading as metabolic targeting. The 3-4× ratio assumes optimal conditions that rarely exist clinically. For BCCs, studies show no meaningful selectivity. For superficial lesions like AKs, minimal selectivity exists but is easily lost with poor technique.
Despite “enormous attention in the field of photodynamic therapy,” researchers admit “only little is known concerning the reasons for the selective accumulation of PpIX in neoplastic tissue”. We’re using a treatment based on selectivity that we don’t understand and that often doesn’t exist.
When PDT works, it’s because the tissue can tolerate broad damage, not because we’re precisely targeting cancer cells. That’s functional medicine, but it’s not the precision therapy that’s marketed to patients paying premium prices for “advanced” treatment.
offshore westerly 